Adherium RPM Revenue Surges 9.4x as Device Shipments Beat Guidance

Adherium's remote patient monitoring subscription revenue surged about 9.4 times over the 12 months to June 2026, as device shipments of 5,300 beat the company's own guidance of roughly 5,000. The ASX-listed respiratory care company now counts more than 2,600 active patients on its Hailie Platform and is targeting around 10,000 by the end of calendar 2026.

Reimbursement runs about US$55 per patient per month under established RPM and remote therapeutic monitoring codes. That recurring revenue stream is the centrepiece of Adherium's shift from a connected-device developer to a commercial respiratory care business built on patient enrolment and retention rather than hardware sales.

Quarterly RPM subscription revenue climbed from $51,000 in the June 2025 quarter to $92,000, then $171,000, then $344,000, before hitting an estimated $479,000 in the June 2026 quarter. The ramp reflects both patient additions and the lag between enrolment and billing.

Adherium's strategy leans on clinical evidence to support both the RPM model and eventual value-based care contracts. The independent iCARE Quality Improvement Program at Intermountain Health reported a 57% reduction in total cost of care, from US$36,837 to US$15,899 per patient per year. Hospital admissions fell 50% and emergency department visits dropped 20%, the program said. The analysis drew on more than 12 million data points from connected devices, wearables and patient-reported information, feeding a behavioural AI platform and pulmonary disease navigators.

Patient retention reached 92% at 12 months and 89.4% at 18 months among 1,049 patients. Adherium expects further clinical and economic data releases over the next six to nine months.

The company has refined enrolment toward moderate-to-severe asthma and chronic obstructive pulmonary disease patients. Recent attrition was concentrated among mild, reliever-only asthma patients with lower perceived need. That narrowed the target population but improved unit economics.

Value-based care represents the longer-term prize. The current RPM model earns recurring revenue by enrolling and managing individual patients. VBC would use the same platform to manage larger cohorts by exception and potentially capture a share of healthcare savings. Multiple national payers are undertaking confidential evaluations of the respiratory program, with finance, pharmacy, and medical teams modelling potential savings through the committee processes that typically precede contracts.

Adherium is targeting continued RPM revenue growth and onboarding optimisation in the first quarter of the 2027 financial year, followed by a first VBC pilot or contract in the second quarter. Shared-savings revenue from an initial VBC arrangement is targeted for the second or third quarter of the 2028 financial year, alongside monetisation of the risk-model and algorithm layer built on Adherium's proprietary dataset.

These milestones remain targets rather than guarantees. No VBC contract has been signed. Adherium's products are not approved for commercial supply in Australia, and the referenced clinical data remains preliminary. The company has expanded its leadership capability across commercial development, finance, product, clinical affairs and VBC as it moves beyond device supply toward broader respiratory care delivery.

The US Food and Drug Administration and Australia's Therapeutic Goods Administration have cleared 12 of Adherium's devices, which span metered dose inhalers and dry powder inhalers. Each generates about 24 objective signals per patient per day.